|
⚲
|
| Keyboard |
| MPM Asset Management LLC
✚
|
|
|---|---|
| CRD # | 148467 |
| SEC # | 801-106989 |
| CIK # | 0001496086, 0001263048 |
| AUM | 3,558.1 M (2026-04-28) |
| Employees | 50 (54% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 617-425-9200 |
| Address | 399 Boylston Street Boston, MA 02116 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (4/28/2026) [Brochure] |
|---|
Item 5. Fees and Compensation The Adviser or its affiliates generally receive Advisory Fees, Performance Allocations, and Carried Interest (each as defined below) or similar performance-based remuneration from a Fund. Performance Allocations, Carried Interest and similar performance-based remuneration is collectively referred to in this brochure as “Incentive Compensation”. A Fund, and/or its portfolio companies may also reimburse the Adviser and its affiliates or its employees, advisors, or consultants for certain expenses and/or make other payments to the Adviser or its affiliates or its employees, advisors, or consultants for services provided to the portfolio companies which, in certain circumstances, reduces the Advisory Fees payable to the Adviser. Additionally, consistent with the Organizational Documents of a Fund, the Fund typically bears certain out-of-pocket expenses incurred by the Adviser in connection with the services provided to the Fund and/or the portfolio companies. Further details about certain common fees and expenses are set forth below. Advisory Fees As compensation for investment supervisory services rendered to the Funds, the Adviser receives from each such Fund an advisory fee (each, an “Advisory Fee”) typically calculated based on committed capital or the value of assets, as determined by the Adviser, with respect to such Fund. Advisory Fees may be reduced during the life of a Fund. The precise amount of, and the manner and calculation of, the Advisory Fees for each Fund are established by the Adviser and are set forth in such Fund’s Organizational Documents. The Advisory Fees and other fees and distributions described herein are generally subject to modification, waiver or reduction by the Adviser in its sole discretion, both voluntarily and on a negotiated basis with selected investors via side letter and other arrangements, which may not be disclosed to other investors in the same Fund. The fee structures described herein may be modified from time to time. Fees may differ from one Fund to another, as well as among investors in the same Fund. Unless otherwise agreed with a Fund’s investors, Advisory Fees will continue to be payable during any term extensions. The Advisory Fees paid by certain Funds will generally be reduced by (1) the fees incurred by the Adviser in connection with the organization of such Fund that exceed a limit specified in such Fund’s Organizational Documents and/or (2) certain Other Fees (as defined and described in more detail below) received by the Adviser or its affiliates. The amount and manner of such reduction, if any, is set forth in the Organizational Documents of the applicable Fund. Advisory Fees vary Fund by Fund and are either payable quarterly or monthly in advance. There are also legacy Advisory Fee and Incentive Compensation structures for certain Funds that are generally no longer available to new investors. Certain investors in the Funds that are employees, business associates and other “friends and family” of the Adviser, its affiliates or their personnel or former personnel, including any related entity established by any of the foregoing, such as trusts, charitable programs, endowments or related programs, family investment vehicles and other estate planning vehicles (collectively, “Adviser Investors”) will not typically pay Advisory Fees in connection with their investment in a Fund. Furthermore, Adviser Investors do not generally bear any expenses incurred in making an investment and, as a result, such expenses are generally borne by the Funds. Adviser Investors will only bear those expenses specifically allocated solely to an Adviser Investor vehicle (for instance, administrative fees, tax preparation fees, state filing fees and similar fees). In addition, the Adviser has in the past and may from time to time in the future establish certain investment vehicles through which certain Adviser Investors, other “friends of the firm,” or other persons may invest alongside one or more Funds in one or more investment opportunities. Such co-investment vehicles generally will not pay Advisory Fees or Incentive Compensation. In addition, as set forth in the Organizational Documents of the applicable Fund, the Adviser and its affiliates, may utilize a “deemed contribution” or “cashless commitment” to satisfy any obligation of the Adviser and certain employees and affiliates of the Adviser to invest in and alongside such Fund and will only be paid in cash if such Fund does not return capital contributed by the limited partners. This “deemed contribution” or “cashless commitment” could result in acceleration of investor capital contributions. The Adviser or an affiliated General Partner deducts Advisory Fees and Incentive Compensation directly from Fund assets and does not bill investors in the Funds. Upon termination of an Advisory Agreement, prepaid Advisory Fees are processed in accordance with the terms of the applicable agreement. Performance Allocations The affiliated General Partner of certain Funds that engage in the trading of public securities receives performance-based compensation generally equal to either 15% or 20% annually of the excess net profit over net losses related to public securities, subject to a high-water mark (the “Performance Allocation”). The Performance Allocation is generally made to the respective General Partner at the end of each year or sooner upon withdrawals by investors. Please see Item 6 below regarding Performance Allocation. Carried Interest Payments With respect to certain Funds, a portion of the profits of each such Fund is distributed to its General Partner, if any, as “carried interest” (the “Carried Interest”), generally equal to 20%. Please see Item 6 below regarding Carried Interest. Other Fees and Expense Reimbursement Other Fees In addition to the Advisory Fees and Incentive Compensation, the Adviser and its affiliates receive ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (4/28/2026) [Brochure] |
|---|
Item 7. Types of Clients The Adviser currently provides investment supervisory services to the Funds. Investment advice is provided directly to the Funds (subject to the direction and control of the General Partner or board of directors of each such Fund, if applicable) and not individually to investors in such Fund. Interests in the Funds are offered pursuant to applicable exemptions from registration under the Securities Act and the 1940 Act. Investors in the Funds are generally “qualified purchasers” as defined in the 1940 Act, and may include, among others, public pension plans, corporate pension plans, endowments, private pension plans, foundations, insurance companies, fund-of-funds, family offices, Operations Support Providers, Entrepreneur Partners, other institutional investors, and high-net worth individuals. The Adviser does not have a minimum size for a Fund, but minimum investment commitments may be established for investors in the Funds. The General Partner or board of directors of each Fund may, in its sole discretion, permit investments below the minimum amounts set forth in the Organizational Documents of such Fund. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Entrada Therapeutics Inc | 25.4 | ||
| Dyne Therapeutics Inc | 8.6 | ||
| Werewolf Therapeutics Inc | 8.5 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | MPM Bioimpact Innovations Equities Master LP | [2025-03-31] | 131.1 M | 253.9 M |
| Filed 2025-06-27 (D/A) · Exemption 3(c)(7), 506(b), 3(c) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| Other | New Technologies and Virology Fund LP | 2025-03-31 | 140.2 M | |
| VC | MPM BioVentures 2022 LP | [2023-03-30] | 351.0 M | 350.7 M |
| Filed 2023-06-01 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $1,050,000 · Revenue Decline to Disclose | ||||
| Other | Oncology Impact Fund 2 LP | [2020-11-17] | 326.8 M | 1,002.8 M |
| Filed 2021-11-22 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $11,919,100 · Revenue Decline to Disclose | ||||
| HF | Bioimpact Equities Master Fund LP | [2020-03-31] | 2.6 M | 90.9 M |
| Filed 2026-03-10 (D/A) · Exemption 506(b) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| VC | MPM Asset Management Investors 2002 Bviii LLC | 2018-03-30 | 0.0 M | |
| VC | MPM Asset Management Investors 2003 Bviii LLC | 2018-03-30 | 1.4 M | |
| VC | MPM Asset Management Investors 2005 Bviii LLC | 2018-03-30 | 0.2 M | |
| VC | MPM Asset Management Investors BV2014 LLC | 2018-03-30 | 4.0 M | |
| VC | MPM Asset Management Investors BV2018 LLC | [2018-03-30] | 7.5 M | 10.5 M |
| Filed 2018-11-09 (D) · Exemption 506(b), 3(c)(1) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 23 | 3.6 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 23 | 3.6 |
| By Discretionary | ||
| Discretionary | 23 | 3.6 |
| Non-Discretionary | 0 | 0.0 |
| Total | 23 | 3.6 |
| By Non-United States Persons | ||
| Non-United States Persons | 2.0 | |
| United States Persons | 1.6 | |
| Total | 23 | 3.6 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Amber Ramsey | Director | 72 | 30 | |
| Nicole Ramroop | Director | 43 | 19 | |
| Alan Kelly | Director | 39 | 17 | |
| Bridget Kidner | Director | 7 | 4 | |
| Howard Rubin | Director, Executive Officer | 11 | 3 | |
| Bronson Crouch | Director | 6 | 3 | |
| Todd Foley | Director, Executive Officer | 42 | 2 | |
| Luke Evnin | Director, Executive Officer, Promoter | 33 | 2 | |
| James Scopa | Director, Promoter | 28 | 2 | |
| Ansbert Gadicke | Director, Executive Officer, Promoter | 27 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001263048] | |
| 3 | [0001263048] | |
| 4 | [0001263048] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Buy | 1,112,777 | $18.00 | 20,029,986 |
|
Aktis Oncology Inc AKTS
Series B Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 6,000,000 | $0.00 | |
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 5,914,197 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 1,577,119 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 1,314,262 | ||
|
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 22,500,000 | $0.00 | |
|
Aktis Oncology Inc AKTS
Series Seed Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 5,000,000 | $0.00 | |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-12-04 | Sell | 83,230 | $0.97 | 80,733 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-12-03 | Sell | 57,225 | $0.87 | 49,786 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-12-02 | Sell | 59,277 | $0.89 | 52,757 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-12-01 | Sell | 60,917 | $0.94 | 57,262 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-28 | Sell | 20,277 | $0.99 | 20,074 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-26 | Sell | 60,733 | $0.98 | 59,518 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-25 | Sell | 42,533 | $0.92 | 39,130 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-24 | Sell | 88,802 | $0.98 | 87,026 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-21 | Sell | 64,331 | $0.83 | 53,395 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-20 | Sell | 41,152 | $0.89 | 36,625 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-19 | Sell | 66,324 | $0.94 | 62,345 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-18 | Sell | 52,627 | $0.93 | 48,943 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-17 | Sell | 57,061 | $0.95 | 54,208 |
| showing 20 of 95 most recent transactions | |||||
| Related Firms | State | AUM |
|---|---|---|
|
MPM Asset Management LLC
✚
|
MA | 3,558.1 M |
|
MPM Oncology Impact Management LP
✚
|
MA |
| Comparable Firms | State | AUM |
|---|---|---|
|
Anchorage Capital Group LLC
✚
|
NY | 3,707.6 M |
|
Resource Capital Investment Corporation
✚
|
CA | 3,706.7 M |
|
Boussard & Gavaudan Investment Management LLP
✚
|
3,679.1 M | |
|
Soleus Capital Management LP
✚
|
CT | 3,663.3 M |
|
Victory Park Capital Advisors LLC
✚
|
IL | 3,647.8 M |
|
First Sentier Investors Australia Infrastructure Managers PTY
✚
|
3,638.1 M | |
|
Axar Capital Management LP
✚
|
NY | 3,598.9 M |
|
Sycamore Tree Capital Partners LP
✚
|
TX | 3,539.6 M |
|
Deer Park Road Management Company LP
✚
|
CO | 3,515.8 M |
|
Hill Path Capital LP
✚
|
NY | 3,408.2 M |